Table 1.
Circulating Biomarkers and Liquid Biopsy |
Tumor Biopsy |
---|---|
Material derived from cancer detectable in bloodstream, urine, or peritoneal fluid | Material obtained from a sampling of tissue lesion |
Non-invasive procedure | High invasive procedure |
Real-time follow up | Impracticable for real-time follow up |
Quick and easily repeatable procedure for obtaining the samples | Difficult to repeat and depend on the correctness of the procedure |
No surgical complication or pain | Risk of surgical complication and pain |
Lack of well-defined practice rules and standardizing protocols | Clinically validated and standard for histologic diagnosis |
Less cost (with some exceptions) | High cost |
Assessment of tumor heterogeneity in different phases of the disease | Failure to reflect tumor heterogeneity |
Low concentrations and easily degradable material | Higher concentration and fixed material |
Less specificity | Higher specificity |
Specialized laboratory | Histology laboratory |